Development based in Switzerland
(VIRUFLEX™) strategiesNext Generation Live-Attenuated SARS-CoV-2 Vaccines
Reverse Genetics (VIRUFLEX™)
and Genotype-to-Phenotype Platform
The reverse genetics platform allows the engineering of viral genomes followed by rapid and efﬁcient recovery of cloned, modiﬁed viruses.
Since 2020, our laboratories generated >250 different SARS-CoV-2 clones.
Attenuating mutations are rationally designed and introduced in a targeted and controlled manner.
This platform differentiates our technology from the ancestral, uncontrolled, time-consuming processes needed to generate attenuated vaccines.
The characteristics of our vaccines, as well as their pre-clinical safety, immunogenicity and efﬁcacy are assessed in primary airway cell cultures and well- established animal models.